SAN DIEGO, Aug. 3, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
technologies designed to provide physicians with clinically
actionable information to improve patient outcomes, announces it
has received more than 7,000 and processed more than 6,500 COVID-19
specimens to date using RT-PCR technology at its CLIA-certified,
CAP-accredited high-complexity molecular lab. The Company has
distributed nearly 12,000 COVID-19 PCR specimen collection kits to
date, and has approximately 18,000 additional collection kits
assembled and available for immediate distribution. The vast
majority of COVID-19 test results were reported to healthcare
providers within 48 hours of receipt of the specimen.
"We are proud to reach this milestone and to serve our community
by providing highly accurate PCR-based COVID-19 diagnostic testing
with a quick turnaround time," said Michael
Nall, President and CEO of Biocept. "We have
distributed specimen collection kits to clinics, hospitals,
corporate clients and skilled nursing facilities, among other
health providers, and new customers are ordering each
week. The number of specimens we received also has increased
each week since we began distributing specimen collection kits in
late June. Given the resurgence in COVID-19 cases, we expect
demand for our testing services to remain high. We have assembled
over 30,000 specimen collection kits available to date and have
reordered components for an additional 20,000 specimen collection
kits, while we continue developing our own kits, which we expect
will be ready for distribution later this quarter.
"We are fortunate to have highly qualified and dedicated
laboratory technicians, cutting-edge testing instrumentation, and
an increasing supply of collection kits," he added. "We are
increasing our COVID-19 testing capacity by allocating more lab
staff to key roles focused on this need, streamlining our workflow
through automated electronic test ordering and accessioning, and
the reporting of testing results through a direct interface with
the California Reportable Disease Information Exchange
(CalREDIE)."
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding the ability of our tests to provide clinically
actionable information, the demand for our COVID-19 testing
services remaining high, the availability and timing of delivery of
additional specimen collection kits from outside sources or
Biocept, our ability to maintain and/or increase our COVID-19
testing capacity and provide timely results, and the ability of
Biocept's platform to identify cancer mutations and alterations to
inform physicians about a patient's disease and therapeutic
options, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our Securities
and Exchange Commission (SEC) filings. The effects of such risks
and uncertainties could cause actual results to differ materially
from the forward-looking statements contained in this release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC, which can be accessed over the
Internet at the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-reaches-covid-19-testing-milestone-with-more-than-7-000-specimens-received-and-more-than-6-500-specimens-processed-301104515.html
SOURCE Biocept, Inc.